Dr. Lansberg is a lipidologist and senior clinical staff member at the Department of Pediatrics, Section Molecular Genetics University Medical Center Groningen. Dr. Lansberg obtained his Bachelor, Master and Doctor of Medicine degrees from University of Amsterdam (UvA). He returned to Academic Medical Center (AMC) where he worked on his doctoral thesis “The Molecular Basis and Treatment of Familial Hypercholesterolemia (FH)” at the department of vascular Medicine under the supervision of prof. John Kastelein and prof. Jan Wouter ten Cate.

He established and supervised the Amsterdam Lipid Clinic in the Slotervaart medical center in Amsterdam and during the 1990ies he co-founded, in collaboration with Prof. Kastelein, the Dutch Lipid Clinic Network, a national alliance of Dutch academic and general hospitals. For this network he conceived and promoted the Dutch Lipid Clinic Diagnostic Criteria for FH. Parallel to the national activities he was active in the international ‘Make Early Diagnosis to Prevent Early Death’ (MedPed) program, initiated by the late Dr. Roger Williams. His focus in both organizations was on developing comprehensive educational programs to improve the clinical management of Familial Hypercholesterolemia patients as well setting up the first electronic health record for the registration of patients with lipid abnormalities in 1990. During this period he was involved in a large number of clinical trials focusing on lipid management and genetic research at the department of vascular medicine at the AMC.

Dr. Lansberg was invited by the Dutch health authorities to develop and lead the National Screening program for FH in 2000. This became the successful Dutch National FH Cascade Screening program, conducted by the “Stichting Opsporing Erfelijke Hypercholesterolemie” (StOEH). He supported similar initiatives in Europe, Middle East, Southeast Asia, Canada, Australia and New Zealand and shared his experience and expertise, building and managing the Dutch FH screening program.

From 2008 – 2016, dr. Lansberg has been active in the field of translational medicine. He established the Durrer Center for Cardiogenetic Research. A national biobank initiative for the Interuniversity Cardiology Institute of the Netherlands (ICIN) and funded by the Dutch Academy of Science and the Dutch Heart Foundation. During the same period, he was the program manager and WP leader Biobanking for the Center for Translational Medicine (CTMM) and Translational Research IT (TraIT) program. CTMM-TraIT is organized as a public-private partnership consortium aiming to organize, deploy and manage a National IT infrastructure for data and workflow management, targeted specifically at the needs of investigator driven, multi-center, translational research projects.

In 2019, he was invited as faculty member of the Executive Committee for the Regional Federation for Europe of the International Atherosclerosis Society (IAS).

Parallel to his scientific and clinical activities dr. Lansberg has given over 1200 presentations and workshops at national and international conferences on cardiovascular risk management, lipids and the prevention of atherosclerosis in more than 70 countries. Based on his broad presentation expertise he now conducts workshops for medical specialists and researchers to improve their presenting and communications skills.